ERIC Recommendations on p53 Dysfunction Analysis in Chronic Lymphocytic Leukamia Patients
Background
Tumor suppressor p53 plays a crucial role in cell cycle regulation and its dysfunction in chronic lymphocytic leukemia is associated with poor prognosis. Inactivation of TP53 gene occurs on average in 10-15% of CLL patients; in majority of cases the 17p deletion is accompanied by TP53 mutation. Recently it has been shown that TP53 mutation itself (inactivation of one allele) occures in a significant proportion of CLL patients with p53 dysfunction and also leads to their inferior prognosis.
Goal
He goal of this project is to define when and how to analyse TP53 status (both mutations and 17p deletions) in CLL patients. The member of the project group should reach the consensus which patients should be tested and in which stage of the disease. The recommendation of several methodologies suitable for TP53 analysis should be provided including the comments of their advantages / disadvantages and clinical utility.
Participants
Sarka Pospisilova, Brno/Czech Republic
Stephan Stilgenbauer, Ulm/Germany
Thorsten Zenz, Heidelberg/Germany
David Gonzales-de-Castro, Sutton/UK
Jitka Malcikova, Brno/Czech Republic
Martin Trbusek, Brno/Czech Republic
Time-line
2011
Coordination
Sarka Pospisilova, PhD.
Brno, Czech Republic
E-mail:
Stephan Stilgenbauer, MD, PhD., Ulm/Germany
Thorsten Zenz, MD, PhD., Heidelberg/Germany
